Total neoadjuvant therapy for rectal cancer: Making sense of the results from the RAPIDO and PRODIGE 23 trials.

[1]  H. Putter,et al.  Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. , 2020, The Lancet. Oncology.

[2]  R. Labianca,et al.  Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials. , 2020, The Lancet. Oncology.

[3]  T. Vuong,et al.  Optimizing Treatment Sequencing of Chemotherapy for Patients with Rectal Cancer: the KIR Randomized Phase II Trial. , 2020, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[4]  T. Gruenberger,et al.  Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  E. Vicaut,et al.  NORAD01-GRECCAR16 multicenter phase III non-inferiority randomized trial comparing preoperative modified FOLFIRINOX without irradiation to radiochemotherapy for resectable locally advanced rectal cancer (intergroup FRENCH-GRECCAR- PRODIGE trial) , 2020, BMC Cancer.

[6]  F. Lordick,et al.  ESMO management and treatment adapted recommendations in the COVID-19 era: colorectal cancer , 2020, ESMO Open.

[7]  M. Buyse,et al.  Outcome measures in multimodal rectal cancer trials. , 2020, The Lancet. Oncology.

[8]  H. Putter,et al.  Compliance and tolerability of short-course radiotherapy followed by preoperative chemotherapy and surgery for high-risk rectal cancer - Results of the international randomized RAPIDO-trial. , 2020, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[9]  G. Fontanini,et al.  Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. , 2020, The Lancet. Oncology.

[10]  R. Yarden,et al.  Colorectal cancer care in the age of coronavirus: strategies to reduce risk and maintain benefit , 2020, Colorectal Cancer.

[11]  L. Moretti,et al.  Adjuvant chemotherapy for rectal cancer: Current evidence and recommendations for clinical practice. , 2019, Cancer treatment reviews.

[12]  L. Moretti,et al.  Grey areas and evidence gaps in the management of rectal cancer as revealed by comparing recommendations from clinical guidelines. , 2019, Cancer treatment reviews.

[13]  Joon-Oh Park,et al.  Oxaliplatin-Based Adjuvant Chemotherapy for Rectal Cancer After Preoperative Chemoradiotherapy (ADORE): Long-Term Results of a Randomized Controlled Trial. , 2019, Journal of Clinical Oncology.

[14]  D. Ren,et al.  Neoadjuvant Modified FOLFOX6 With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer: Final Results of the Chinese FOWARC Trial , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  R. Jain,et al.  Effect of Aflibercept Plus Modified FOLFOX6 Induction Chemotherapy Before Standard Chemoradiotherapy and Surgery in Patients With High-Risk Rectal Adenocarcinoma: The GEMCAD 1402 Randomized Clinical Trial. , 2019, JAMA oncology.

[16]  J. Kładny,et al.  Long-course preoperative chemoradiation vs. 5 x 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: Long-term results of the randomized Polish II study. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  T. Friede,et al.  Randomized Phase II Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: CAO/ARO/AIO-12. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  B. Glimelius,et al.  Tumour regression after radiotherapy for rectal cancer - Results from the randomised Stockholm III trial. , 2019, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[19]  I. Nagtegaal,et al.  An overview of 25 years of incidence, treatment and outcome of colorectal cancer patients , 2018, International journal of cancer.

[20]  I. Edhemovic,et al.  Induction Chemotherapy, Chemoradiotherapy and Consolidation Chemotherapy in Preoperative Treatment of Rectal Cancer - Long-term Results of Phase II OIGIT-01 Trial , 2018, Radiology and oncology.

[21]  B. Karabulut,et al.  Randomized clinical trial of short or long interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer , 2018, The British journal of surgery.

[22]  C. Hurt,et al.  A prospective phase II study of pre-operative chemotherapy then short-course radiotherapy for high risk rectal cancer: COPERNICUS , 2018, British Journal of Cancer.

[23]  J. Joo,et al.  A Randomized Phase 2 Trial of Consolidation Chemotherapy After Preoperative Chemoradiation Therapy Versus Chemoradiation Therapy Alone for Locally Advanced Rectal Cancer: KCSG CO 14-03. , 2018, International journal of radiation oncology, biology, physics.

[24]  G. Beets,et al.  Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study , 2018, The Lancet.

[25]  D. Ryan,et al.  Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer-The New Standard of Care? , 2018, JAMA oncology.

[26]  M. Gonen,et al.  Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer , 2018, JAMA oncology.

[27]  M. Thomas,et al.  Prospective randomized trial of neoadjuvant chemotherapy during the ‘wait period’ following preoperative chemoradiotherapy for rectal cancer: results of the WAIT trial , 2017, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[28]  L. Wyrwicz,et al.  Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  H. Johansson,et al.  Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial. , 2017, The Lancet. Oncology.

[30]  D. Tait,et al.  Results of a prospective randomised control 6 vs 12 trial: Is greater tumour downstaging observed on post treatment MRI if surgery is delayed to 12-weeks versus 6-weeks after completion of neoadjuvant chemoradiotherapy? , 2016 .

[31]  H. Zhang,et al.  Modified FOLFOX6 With or Without Radiation Versus Fluorouracil and Leucovorin With Radiation in Neoadjuvant Treatment of Locally Advanced Rectal Cancer: Initial Results of the Chinese FOWARC Multicenter, Open-Label, Randomized Three-Arm Phase III Trial. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  D. Tait,et al.  PAN-EX: a pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancer. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[33]  A. Dybko,et al.  Long-course oxaliplatin-based preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[34]  G. Fontanini,et al.  FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. , 2015, The Lancet. Oncology.

[35]  T. Hickish,et al.  Short- and Long-Term Quality of Life and Bowel Function in Patients With MRI-Defined, High-Risk, Locally Advanced Rectal Cancer Treated With an Intensified Neoadjuvant Strategy in the Randomized Phase 2 EXPERT-C Trial. , 2015, International journal of radiation oncology, biology, physics.

[36]  David D. Smith,et al.  Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. , 2015, The Lancet. Oncology.

[37]  J. Monson,et al.  Extended Intervals after Neoadjuvant Therapy in Locally Advanced Rectal Cancer: The Key to Improved Tumor Response and Potential Organ Preservation. , 2015, Journal of the American College of Surgeons.

[38]  C. Montagut,et al.  Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial†. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[39]  H. Putter,et al.  Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[40]  P. Lambin,et al.  Selection of appropriate end-points (pCR vs 2yDFS) for tailoring treatments with prediction models in locally advanced rectal cancer. , 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[41]  H. Putter,et al.  Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data. , 2015, The Lancet. Oncology.

[42]  D. Cunningham,et al.  Neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer. , 2014, Future oncology.

[43]  X. An,et al.  Neoadjuvant sandwich treatment with oxaliplatin and capecitabine administered prior to, concurrently with, and following radiation therapy in locally advanced rectal cancer: a prospective phase 2 trial. , 2014, International journal of radiation oncology, biology, physics.

[44]  C. Orlandini,et al.  No benefit of adjuvant Fluorouracil Leucovorin chemotherapy after neoadjuvant chemoradiotherapy in locally advanced cancer of the rectum (LARC): Long term results of a randomized trial (I-CNR-RT). , 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[45]  P. Quirke,et al.  Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control. , 2014 .

[46]  K. Goodman,et al.  Neoadjuvant chemotherapy first, followed by chemoradiation and then surgery, in the management of locally advanced rectal cancer. , 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

[47]  L. Collette,et al.  Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. , 2014, The Lancet. Oncology.

[48]  C. Buskens,et al.  Optimal time interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer , 2013, British Journal of Surgery.

[49]  D. Goldstein,et al.  Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  K. Vistisen,et al.  Induction chemotherapy with capecitabine and oxaliplatin followed by chemoradiotherapy before total mesorectal excision in patients with locally advanced rectal cancer. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[51]  R. Glynne-Jones,et al.  Neoadjuvant chemotherapy in MRI-staged high-risk rectal cancer in addition to or as an alternative to preoperative chemoradiation? , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[52]  D. Franchimont,et al.  Short course chemotherapy followed by concomitant chemoradiotherapy and surgery in locally advanced rectal cancer: a randomized multicentric phase II study. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[53]  D. Tait,et al.  Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C). , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  T. Beißbarth,et al.  Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  Hein Putter,et al.  Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. , 2011, The Lancet. Oncology.

[56]  D. Tait,et al.  Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial. , 2010, The Lancet. Oncology.

[57]  S. Polo,et al.  Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer d , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  C. Bokemeyer,et al.  A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[59]  R. Greil,et al.  Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  A. Zaitoun,et al.  Regression of rectal cancer with radiotherapy with or without concurrent capecitabine--optimising the timing of surgical resection. , 2009, Clinical oncology (Royal College of Radiologists (Great Britain)).

[61]  L. Crinò,et al.  Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  K. Bujko,et al.  Long‐term results of a randomized trial comparing preoperative short‐course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer , 2006, The British journal of surgery.

[63]  A. Makris,et al.  Neoadjuvant chemotherapy prior to preoperative chemoradiation or radiation in rectal cancer: should we be more cautious? , 2006, British Journal of Cancer.

[64]  J. Kładny,et al.  Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy. , 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[65]  A. Norman,et al.  Neoadjuvant systemic fluorouracil and mitomycin C prior to synchronous chemoradiation is an effective strategy in locally advanced rectal cancer , 2003, British Journal of Cancer.